BioMimetic Therapeutics was the market's biggest loser, shedding nearly 30% of its value after its bone graft device was dealt a setback in the approval process from the Food and Drug Administration.

Mobile chip designer Spreadtrum took a hit -- with a 22% drop on Friday alone -- after RF Micro Devices pointed the finger at softening demand from its China-based customers.

Investors threw the book -- and Nook -- at Barnes & Noble after the company dramatically hosed down the guidance for its EBITDA and bottom-line results for its current fiscal year. The company's Nook business is going well, at least outside of disappointing sales for its entry-level e-reader. However, steep losses in that business find the bookseller exploring the separation of its two major businesses.

Telestone is another heartbreaker. The Beijing-based supplier of local access network solutions for communications networks updated its guidance for the fiscal year that just ended. Telestone sees revenue growth of just 15%, half the pace it had projected earlier. Did it really have to wait until the end of the year to publicly concede that point?

Finally, we have Angie's List fishing for referrals on a good pain healer. Analysts finally chimed in with public opinions on the company, and it wasn't pretty. Just three of the eight pros offered "buy" ratings, and those three helped take the company public two months ago.

Author

Rick has been writing for Motley Fool since 1995 where he's a Consumer and Tech Stocks Specialist. Yes, that's a long time. He's been an analyst for Motley Fool Rule Breakers and a portfolio lead analyst for Motley Fool Supernova since each newsletter service's inception. He earned his BBA and MBA from the University of Miami, and he now lives a block from his alma mater.
Follow @market